Kymera Investor Presentation Deck

● MDM2 is the E3 Ligase that Modulates p53, the Largest Tumor Suppressor Cancer genetics: p53 is NOT mutated in almost 50% of tumors • MDM2 overexpression and amplification can inactivate p53 Large opportunity in wide variety of cancers ● ● ● ● MDM2 Degraders In Oncology: KT-253 ● Benefits of MDM2 Degradation KT-253, unlike small molecule inhibitors, overcomes the feedback loop which up-regulates MDM2 production and in doing so more effectively stabilizes the tumor suppressor p53 Broad franchise opportunities available for this mechanism (over 50% of tumors are p53 WT), Kymera is focused on indications with specific sensitivity to degrader mechanism, through a biomarker strategy Opportunity to translate profile into clinical superiority of degrader over SMI, as has been shown with IRAK4 KYMERA ©2023 KYMERA THERAPEUTICS, INC. MDM2 CRISPR Sensitivity Score 0.6 Dependency of p53WT cells on MDM2 0.4 0.2 0 -0.2 -0.4 -0.6 -0.8 -1 -1.2 -1.4 -1.6 -1.8 -2 -2.2 p53MUT p53WT DNA Damage p53 Graph generated with data obtained from DepMap.org Cell Line Stressors Hypoxia Oncogenes MDM2 p53 p53 ub ub MDM2 Tumor Suppression Other p53 Targets CE p53 Degradation Feedback Loop Cell Cycle Arrest (p21, Ptprv) Apoptosis (Noxa, Bax, Puma) PAGE 51

View entire presentation